Lipid/Metabolic
FDA advisory panel votes in favor of broadened rosuvastatin indication
10 COMMENTS - Dec 15, 2009 17:10 EST
UPDATED // The advisory panel voted 12 to 4 in favor of expanding the indication for rosuvastatin to include men and women >50 and >60 years old, respectively, with elevated CRP levels, normal LDL-cholesterol levels, and without any other cardiovascular-disease risk equivalents.
Medscape Medical News
Intensive medical therapy in asymptomatic carotid stenosis helps reduce microemboli and CV risk
7 COMMENTS - Dec 16, 2009 16:15 EST
UPDATED // Intensive medical therapy markedly reduces the incidence of microemboli and CV risk in asymptomatic carotid stenosis, as compared with people receiving less intensive treatment. Authors of the study believe intensive medical therapy should be the first-line approach in asymptomatic CS patients.
Acute Coronary Syndromes
UK scientists unearth potential new biomarker for MI
1 COMMENT - Dec 15, 2009 14:45 EST
British researchers have unearthed a new protein that they hope could become an even better biomarker than troponins for MI; the novel marker offers the promise of accurately mapping the course of a heart attack, they say.
heartbriefs
heartbriefs
View all »
Editorial series
A series of discussions among editorial leaders, developed by theheart.org

Editorial series
Is there a future for cangrelor after CHAMPION?
Dec 10, 2009 12:00 EST
heartwire's Sue Hughes talks to Drs Bob Harrington, Gregg Stone, and Sanjay Kaul about cangrelor and why the CHAMPION trials didn't do it justice.
Editorial series
Perspectives from AHA 2009: Wrapping up the Scientific Sessions with Clyde Yancy and Nancy Brown
Dec 2, 2009 11:15 EST
AHA president Dr Clyde Yancy and CEO Nancy Brown share insights from the recent sessions and discuss ongoing initiatives with heartwire's Shelley Wood.
The Cardiology Show
The AHA 2009 Roundup: ARBITER 6-HALTS, PLATO, the two CHAMPIONs, and CASCADE
3 COMMENTS - Nov 18, 2009 16:30 EST
Join Drs Valentin Fuster, Roger Blumenthal, Bob Harrington, Judith Hochman, Sanjay Kaul, Suzanne Oparil, Gregg Stone, Lynne Warner Stevenson, and Bruce Wilkoff as they discuss important news from the Scientific Sessions and tackle the issue of too little, too soon in clinical trials today.
Editorial series
New directions for management of patients with atrial fibrillation
Nov 11, 2009 09:50 EST
New agents and interventions are paving the way for revised modalities in the management of patients with atrial fibrillation. Join Drs Alpert and Delascio Lopes for a review of the latest findings and options.
Discussion and opinions
Lively, interactive exchanges moderated by thought leaders, staff or contributors to theheart.org

Topolog
Twitter: A place in the medical world?
Wed Dec 16 10:30:00 EST 2009
It appears to be more than a passing fad. Can micro-messaging serve a practical purpose in our world of healthcare and research?
theheart.org Forum
Discussions among healthcare providers, clinicians, and researchers.
Visit the forum »
Heart failure
Survival with ICD in heart failure: "Real-world" experience on par with trials
Dec 16, 2009 17:45 EST
Hospitalized, ICD-eligible patients with heart failure, generally older than those in the relevant trials, benefit with a 29% lower risk of dying if they actually receive such a device, according to a registry experience.
Hypertension
Darusentan disappoints in DORADO-AC; company to drop the drug
Dec 15, 2009 13:45 EST
CORRECTED // The sponsor of the trial, also known as DAR-312, testing the endothelin receptor antagonist darusentan says the drug failed to live up to the successes of its earlier phase 3 trial.
Lipid/Metabolic
Treatment to low glucose targets cuts CV risk in less-sick diabetics: Cohort study
Dec 14, 2009 17:00 EST
A prospective cohort study supports the view, largely based on post hoc analyses, that treating diabetics with multiple or severe comorbidities to achieve HbA1c levels of <6.5% or <7.0% is unlikely to reduce their risk of cardiovascular events.
Lipid/Metabolic
High-dose statin therapy reduces recurrent cardiovascular events
3 COMMENTS - Dec 14, 2009 16:45 EST
The post hoc exploratory findings from the PROVE-IT-TIMI 22 and IDEAL studies highlight the need for clinicians to continue to prescribe high-dose statin therapy to patients experiencing a first cardiovascular event, say researchers.
Imaging
Computer simulation shows CT may be cost-effective option for chest pain
Dec 14, 2009 13:15 EST
A computer model based on clinical data suggests CCTA may be a cost-effective approach to early evaluation of ambulatory chest-pain patients.
Interventional/Surgery
First randomized study of endovascular aortic repair offers more questions, few answers
1 COMMENT - Dec 11, 2009 17:45 EST
Thoracic endovascular aortic repair failed to improve two-year survival and adverse-event rates despite favorable aortic remodeling in the randomized INSTEAD trial, but the potential role of stent grafts in these patients is still unclear.
Prevention
FDA panel readies to review expanded rosuvastatin label
3 COMMENTS - Dec 11, 2009 16:15 EST
The panel will review the company's bid to broaden the labeling for this statin to include people with normal LDL levels but high CRP. The application is based on the positive findings from the JUPITER trial.
Medscape Medical News
Adverse lipid changes seen during transition to menopause
Dec 11, 2009 16:00 EST
A new study underscores the need to closely monitor lipids in midlife women for primary heart-disease prevention.
Medscape Medical News
Smoking cessation confers survival benefits after first AMI
Dec 11, 2009 14:45 EST
Lifetime nonsmokers and those who quit before or after a first acute MI have lower mortality rates than current smokers.
Prevention
Low-carb diets hit the headlines again
1 COMMENT - Dec 11, 2009 13:15 EST
UPDATED //A small study in only 24 patients and lasting just eight weeks has once again thrust low-carb diets into the spotlight, with the finding that this diet adversely affected a little-known measure of arterial stiffness, the aortic-augmentation index, which could have implications for long-term vascular health.
Educational partnerships


  • What Happened at AHA 2009?

    The Cleveland Clinic Perspective
    Drs. Nissen, Young, and Becker discuss the latest on the new antiplatelet agents, ticagrelor and cangrelor, the ARBITER 6-HALTS and HeartMate II study, and destination therapy for patients that are not eligible for heart transplantation.


  • What Happened at CCC 2009?

    A University of Alberta Perspective
    Drs. Armstrong, Ezekowitz, and Welsh as they discuss the latest data to come out of the 2009 sessions of the Canadian Cardiovascular Congress, from Edmonton, Alberta.


  • What Happened at ESC 2009?

    DUKE Heart Center and DUKE Clinical Research Institute
    Drs. Rao, Alexander, Newby, and O'Connor discuss RE-LY, PLATO, and MADIT-CRT.


  • What Happened at ESC 2009?

    Mayo Clinic
    Drs. Gibbons and Jaffe discuss Antiplatelet therapy in ACS, Atrial Fibrillation, Higher dose clopidogrel and aspirin and CRT therapy in patients with Class I or II heart failure.


  • What Happened at HFSA 2009?

    Cleveland Clinic
    Drs. Young, Starling, and Mountis discuss the latest on cardiac resynchronization, ICDs, exercise and heart failure, women in clinical trials, and guidelines.

Most popular
  1. FDA advisory panel votes in favor of broadened rosuvastatin indication
  2. First randomized study of endovascular aortic repair offers more questions, few answers
  3. Darusentan disappoints in DORADO-AC; company to drop the drug
  4. Mounting debate over aspirin use in primary prevention should prompt new talks with patients
  5. Low-carb diets hit the headlines again
  6. FDA panel readies to review expanded rosuvastatin label
  7. PROTECT halted: Event rates fall by treating HF with natriuretic-peptide guidance
  8. UK scientists unearth potential new biomarker for MI
  9. High-dose statin therapy reduces recurrent cardiovascular events
  10. Adverse lipid changes seen during transition to menopause
View all news »
  1. Smoking promotes heart allograft rejection in rat study
  2. FDA advisory panel votes in favor of broadened rosuvastatin indication
  3. Mounting debate over aspirin use in primary prevention should prompt new talks with patients
  4. Intensive medical therapy in asymptomatic carotid stenosis helps reduce microemboli and CV risk
  5. Proposed device tax in health reform bill creates angst among device makers and cardiologists
  6. theheart.org blogger finally gets go-ahead for PCI without surgical backup
  7. Vitamin D: A potential role in cardiovascular disease prevention
  8. High-dose statin therapy reduces recurrent cardiovascular events
  9. FDA panel readies to review expanded rosuvastatin label
  10. UK diabetic cohort analysis confirms sulfonylurea risks, adds to glitazone debate
View all discussions »
button

The Heart of a Woman
Drs. Hayes and Foody and a committee of experts address the gaps and correct the misconception that CVD is more common in men than women.
View all programs »
View all »
Info from Industry
Also on theheart.org
Features
Mounting debate over aspirin use in primary prevention should prompt new talks with patients
10 COMMENTS - Dec 9, 2009 08:30 EST
The year kicked off with some rosy recommendations from the USPSTF, but a steady accumulation of studies suggest that aspirin's risks may eclipse its benefits in preventing initial cardiac and cerebrovascular events—most strikingly, a report from the same group that bolstered the primary-prevention case for aspirin in the first place. Everyone agrees: it's time to talk to your patients about aspirin.
Acute Coronary Syndromes
Improving Outcomes in STEMI: Management of Adjunctive Antithrombotic Therapy in ACS
Nov 26, 2009 11:27 EST
Our international panel of experts, Drs. Hamm, Verheugt, Dauerman, and Rao, give their insights into which antiplatelet and antithrombotic agents they prefer to use and when.
The Cardiology Show
The AHA 2009 Roundup: ARBITER 6-HALTS, PLATO, the two CHAMPIONs, and CASCADE
3 COMMENTS - Nov 18, 2009 16:30 EST
Join Drs Valentin Fuster, Roger Blumenthal, Bob Harrington, Judith Hochman, Sanjay Kaul, Suzanne Oparil, Gregg Stone, Lynne Warner Stevenson, and Bruce Wilkoff as they discuss important news from the Scientific Sessions and tackle the issue of too little, too soon in clinical trials today.